Asset
EVORPACEPT
ALX Oncology Holdings Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04417517 | phase1 | terminated | 2020-10-02 | 2025-01-17 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) |
| NCT05524545 | phase1 | completed | 2022-11-02 | 2025-06-27 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) |
| NCT04755244 | phase1 | terminated | 2021-05-05 | 2023-05-05 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) |
| NCT05002127 | phase2_3 | active_not_recruiting | 2022-01-15 | 2024-05-24 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) |
| NCT03013218 | phase1 | completed | 2017-02-03 | 2022-02-01 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) |
FDA applications (0)
This company has no applications containing this asset.